Found: 31
Select item for more details and to access through your institution.
A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 9, p. 1713, doi. 10.1111/cts.13585
- By:
- Publication type:
- Article
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
- Published in:
- Cancers, 2023, v. 15, n. 16, p. 4034, doi. 10.3390/cancers15164034
- By:
- Publication type:
- Article
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1081, doi. 10.1007/s10637-021-01086-6
- By:
- Publication type:
- Article
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 6, p. 1836, doi. 10.1007/s10637-020-00968-5
- By:
- Publication type:
- Article
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 536, doi. 10.1007/s10637-017-0545-x
- By:
- Publication type:
- Article
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
- Published in:
- Journal of Surgical Oncology, 2018, v. 117, n. 8, p. 1679, doi. 10.1002/jso.25097
- By:
- Publication type:
- Article
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 5, p. 584, doi. 10.1007/s10637-016-0370-7
- By:
- Publication type:
- Article
Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: A Randomized, Controlled, Biomarker Study.
- Published in:
- PLoS ONE, 2014, v. 9, n. 4, p. 1, doi. 10.1371/journal.pone.0095310
- By:
- Publication type:
- Article
Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0084417
- By:
- Publication type:
- Article
A comparative small-animal PET evaluation of [C]tariquidar, [C]elacridar and ( R)-[C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2012, v. 39, n. 1, p. 149, doi. 10.1007/s00259-011-1941-7
- By:
- Publication type:
- Article
The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils.
- Published in:
- PLoS ONE, 2012, v. 7, n. 1, p. 1, doi. 10.1371/journal.pone.0029925
- By:
- Publication type:
- Article
Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo.
- Published in:
- Journal of Investigative Dermatology, 2011, v. 131, n. 2, p. 495, doi. 10.1038/jid.2010.327
- By:
- Publication type:
- Article
A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication-Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1.
- Published in:
- Journal of Infectious Diseases, 2010, v. 201, n. 3, p. 354, doi. 10.1086/649428
- By:
- Publication type:
- Article
BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo.
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
- Published in:
- 2010
- By:
- Publication type:
- Abstract
mTORC1 inhibition with rapamycin or LY294002 alone but not in combination leads to AKT phosphorylation via mTORC2 in melanoma cells.
- Published in:
- BMC Pharmacology, 2007, v. 7, p. 1, doi. 10.1186/1471-2210-7-S2-A25
- By:
- Publication type:
- Article
Thalidomide Enhances the Anti-Tumor Activity of Standard Chemotherapy in a Human Melanoma Xenotransplatation Model.
- Published in:
- Journal of Investigative Dermatology, 2005, v. 125, n. 2, p. 201, doi. 10.1111/j.0022-202X.2005.23830.x
- By:
- Publication type:
- Article
Clusterin Regulates Drug-Resistance in Melanoma Cells.
- Published in:
- Journal of Investigative Dermatology, 2005, v. 124, n. 6, p. 13, doi. 10.1111/j.0022-202X.2005.23720.x
- By:
- Publication type:
- Article
Pegylated and Conventional Interferon-α Induce Comparable Transcriptional Responses and Inhibition of Tumor Growth in a Human Melanoma SCID Mouse Xenotransplantation Model.
- Published in:
- Journal of Investigative Dermatology, 2004, v. 123, n. 4, p. 664, doi. 10.1111/j.0022-202X.2004.23433.x
- By:
- Publication type:
- Article
Loss of Novel mda-7 Splice Variant ( mda-7s) Expression is Associated with Metastatic Melanoma<sup>1</sup>.
- Published in:
- Journal of Investigative Dermatology, 2004, v. 123, n. 3, p. 583, doi. 10.1111/j.0022-202X.2004.23321.x
- By:
- Publication type:
- Article
CpG Oligonucleotides Elicit Antitumor Responses in a Human Melanoma NOD/SCID Xenotransplantation Model.
- Published in:
- Journal of Investigative Dermatology, 2004, v. 122, n. 2, p. 387, doi. 10.1046/j.0022-202X.2004.22202.x
- By:
- Publication type:
- Article
A novel concept for ligand attachment to oligonucleotides via a 2′‐succinyl linker.
- Published in:
- Nucleic Acids Research, 2004, v. 32, n. 2, p. 710, doi. 10.1093/nar/gkh229
- By:
- Publication type:
- Article
Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells.
- Published in:
- Head & Neck, 2003, v. 25, n. 9, p. 732
- By:
- Publication type:
- Article
Mcl-1 Antisense Therapy Chemosensitizes Human Melanoma in a SCID Mouse Xenotransplantation Model.
- Published in:
- Journal of Investigative Dermatology, 2003, v. 120, n. 6, p. 1081, doi. 10.1046/j.1523-1747.2003.12252.x
- By:
- Publication type:
- Article
Farnesyl Thiosalicylic Acid Chemosensitizes Human Melanoma In Vivo.
- Published in:
- Journal of Investigative Dermatology, 2003, v. 120, n. 1, p. 109, doi. 10.1046/j.1523-1747.2003.12009.x
- By:
- Publication type:
- Article
Bcl-xL Antisense Oligonucleotides Chemosensitize Human Glioblastoma Cells.
- Published in:
- Chemotherapy (0009-3157), 2002, v. 48, n. 4, p. 189, doi. 10.1159/000063873
- By:
- Publication type:
- Article
Bcl-X.
- Published in:
- International Journal of Cancer, 2002, v. 99, n. 1, p. 29, doi. 10.1002/ijc.10248
- By:
- Publication type:
- Article
Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
- Published in:
- Journal of Molecular Medicine, 2001, v. 79, n. 10, p. 587, doi. 10.1007/s001090100251
- By:
- Publication type:
- Article
Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells.
- Published in:
- Journal of Investigative Dermatology, 2000, v. 114, n. 5, p. 935, doi. 10.1046/j.1523-1747.2000.00972.x
- By:
- Publication type:
- Article